Human Papillomavirus type 16 L1 protein / Human Papillomavirus type 18 L1 protein

Key facts

Invented name
Cervarix
Active substance
  • human papillomavirus type 16 L1 protein
  • human papillomavirus type 18 L1 protein
Therapeutic area
Vaccines
Decision number
P/11/2009
PIP number
Human Papillomavirus type 16 L1 protein / Human Papillomavirus type 18 L1 protein
Pharmaceutical form(s)
Suspension for injection
Condition(s) / indication(s)
Infection by Human Papillomavirus in females
Route(s) of administration
Intramuscular injection
Contact for public enquiries
GlaxoSmithKline Biologicals S.A. (Belgium)

E-mail: graeme.x.hacking@gskbio.com
Country: Belgium
Phone: +32 477902000

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating